Jingxin pharmaceutical: rosuvastatin calcium dispersible tablets obtained the approval of drug registration

On May 15, Beijing New Pharmaceutical Co., Ltd issued an enterprise announcement, saying that its company has received the registration approval document of rosuvastatin calcium dispersible tablets (specification 10mg) approved and issued by the State Drug Administration, with the approval document No of gjzz h20193125, and the approval document No is valid until May 4, 2024 Rosuvastatin calcium dispersible tablet is a kind of drug for the treatment of hyperlipidemia It is suitable for the primary hypercholesterolemia (type IIA, including heterozygous family hypercholesterolemia) or mixed type dyslipidemia (type IIB) which can not be properly controlled by diet control and other non drug treatment (such as exercise treatment, weight loss) Rosuvastatin calcium dispersible tablets disintegrated rapidly when exposed to water, especially for the elderly or patients with dysphagia, so as to improve the compliance of patients According to the data of minenet, the sales volume of rosuvastatin tablets at the terminals of public medical institutions in China in 2017 was 5.019 billion yuan AstraZeneca, the original research manufacturer, occupies 56.71% of the market share, while lunanbert pharmaceutical, Jingxin pharmaceutical and Nanjing Zhengda Tianqing pharmaceutical all account for more than 10% In recent years, the market share of risuvastatin calcium tablets in Jingxin pharmaceutical industry has been growing, from 8.88% in 2013 to 13.37% in 2017, while the market share of AstraZeneca dropped from 69.64% in 2013 to 56.71% in 2017 In addition, it is worth mentioning that risuvastatin calcium tablets of Jingxin Pharmaceutical Co., Ltd are selected at the price of 21.8 yuan in the centralized purchase of 4 + 7 urban drugs According to the drug registration and acceptance database, at present, the two specifications of risuvastatin tablets 5mg and 10mg of Zhejiang Jingxin Pharmaceutical Co., Ltd have passed the consistency evaluation Now, risuvastatin calcium dispersible tablets have been approved, further enriching the company's statin products and dosage forms, which is conducive to improving the market competitiveness of the company's cardiovascular and cerebrovascular products And according to Internet news, yesterday Beijing new pharmaceutical industry was approved by the drug, the stock directly up and down.